Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95


Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells.

Wu K, Chang Q, Lu Y, Qiu P, Chen B, Thakur C, Sun J, Li L, Kowluru A, Chen F.

Oncotarget. 2013 Dec;4(12):2430-8.


Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.

Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.

Int J Oncol. 2013 Jun;42(6):2094-102. doi: 10.3892/ijo.2013.1895.


Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.

Takata M, Chikumi H, Miyake N, Adachi K, Kanamori Y, Yamasaki A, Igishi T, Burioka N, Nanba E, Shimizu E.

Cancer Biol Ther. 2012 Apr;13(6):369-78. doi: 10.4161/cbt.19238.


The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.

Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Lee SS, Kim CH, Yoo YD, Lee JC.

Mol Cancer Res. 2009 Oct;7(10):1736-43. doi: 10.1158/1541-7786.MCR-08-0504.


EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.

Han W, Pan H, Chen Y, Sun J, Wang Y, Li J, Ge W, Feng L, Lin X, Wang X, Wang X, Jin H.

PLoS One. 2011;6(6):e18691. doi: 10.1371/journal.pone.0018691.


Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.

Choi YJ, Rho JK, Jeon BS, Choi SJ, Park SC, Lee SS, Kim HR, Kim CH, Lee JC.

Cancer Chemother Pharmacol. 2010 Jul;66(2):381-8. doi: 10.1007/s00280-009-1174-7.


A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance.

Haura EB, Sommers E, Song L, Chiappori A, Becker A.

J Thorac Oncol. 2010 Nov;5(11):1806-14. doi: 10.1097/JTO.0b013e3181f38f70.


Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.

Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, Longley DB, Johnston PG.

Mol Cancer Ther. 2006 May;5(5):1154-65.


Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation.

Uchida A, Hirano S, Kitao H, Ogino A, Rai K, Toyooka S, Takigawa N, Tabata M, Takata M, Kiura K, Tanimoto M.

Cancer Sci. 2007 Mar;98(3):357-63.


Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.

Huang Y, Chen Y, Mei Q, Chen Y, Yu S, Xia S.

Oncol Rep. 2013 Jun;29(6):2486-92. doi: 10.3892/or.2013.2357.


Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.


Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Review.


AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.

Puglisi M, Thavasu P, Stewart A, de Bono JS, O'Brien ME, Popat S, Bhosle J, Banerji U.

Lung Cancer. 2014 Aug;85(2):141-6. doi: 10.1016/j.lungcan.2014.05.008.


Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.

Pernas FG, Allen CT, Winters ME, Yan B, Friedman J, Dabir B, Saigal K, Mundinger GS, Xu X, Morris JC, Calvo KR, Van Waes C, Chen Z.

Clin Cancer Res. 2009 Apr 1;15(7):2361-72. doi: 10.1158/1078-0432.CCR-08-1011.


Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer.

Edmonds C, Hagan S, Gallagher-Colombo SM, Busch TM, Cengel KA.

Cancer Biol Ther. 2012 Dec;13(14):1463-70. doi: 10.4161/cbt.22256.


Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.

Liu X, Carlisle DL, Swick MC, Gaither-Davis A, Grandis JR, Siegfried JM.

Exp Cell Res. 2007 Apr 15;313(7):1361-72.


Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.

Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S.

Clin Cancer Res. 2012 Mar 15;18(6):1663-71. doi: 10.1158/1078-0432.CCR-11-1171.


Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer.

Li Q, Zhang D, Chen X, He L, Li T, Xu X, Li M.

Sci Rep. 2015 Nov 6;5:16082. doi: 10.1038/srep16082.

Supplemental Content

Support Center